Droplet Digital PCR in Minimal Residual Disease (MRD)

ddpcr for oncology icon

Pioneering Platform Advancing the Field of MRD

Performance to drive progress, results to revolutionize healthcare. Learn why Bio-Rad is the digital PCR market leader through customer case studies.

  • Tumor Response to Therapy Research:

    Neo-adjuvant therapy is often employed to shrink tumors prior to curative treatment efforts. Molecular responses to cancer therapy as measured by ctDNA indicates effect earlier than standard methods, widening the treatment window, allowing a physician to switch to a more effective drug in the case of poor or no response to initial therapy. ddPCR technology is an ultra-sensitive method that can detect molecular responses earlier and more precisely than other commonly adopted molecular technologies.

  • MRD Research:

    Analyzing MRD levels is vital to both indicating achievement of a deep molecular response (remission) in response to oncological therapy as well as potential reoccurrence of cancer (relapse). MRD testing has become widely adopted for monitoring hematological malignancies and is now being implemented for solid tumor diseases. Because disease markers are often in very low abundance in the blood, especially for solid tumors, ddPCR technology is ideal to implement for MRD monitoring given its unmatched sensitivity, precision, and absolute quantitation capabilities.

Droplet Digital PCR Technology in the Field

ctDNA Analysis Powered by ddPCR™ Technology

Learn how ddPCR plays a critical role in lung cancer sample analysis at Biodesix

Gary Pestano, Ph.D
Chief Development Officer



Related Products

The Power of ddPCR Analysis for Lung Cancer Research

Dr. Schuuring discusses how the high sensitivity and absolution quantification capabilities of ddPCR are advancing the field of ctDNA analysis

Ed. Schuuring, Ph.D.
Professor Molecular Pathology
University Medical Center Groningen



Related Products

Discover How ddPCR Powered Pioneering Analysis in Breast Cancer

Dr. Garcia-Murillas discusses his pioneering work in ctDNA analysis for breast cancer, the impact it has had on the field, and how ddPCR continues to power his research.

Isaac Garcia-Murillas, Ph.D.
Staff Scientist
The Institute of Cancer Research


Related Products

Expanding ctDNA Analysis Power with the QX600 Droplet Digital PCR System

Dr. Dobrovic and Dr. Wong, highlight the advantages of ddPCR for liquid biopsy analysis and how multiplexing with the QX600 ddPCR System has streamlined their efforts

Boris Wong, Ph.D.
Medical Scientist
University of Melbourne, Austin Health

Dr. Alexander Dobrovic
Head of Translational Genomics and Epigenomics
University of Melbourne, Austin Health


Related Products


More about ddPCR in MRD

Sign Up to Be the First to Know


Receive ddPCR Technology and MRD Updates

Sign up to be notified when new ddPCR technology and MRD related resources like tips and tricks, posters, protocols and webinars become available.


Oncology/MRD/ctDNA Analysis:

Increasing Clinical Trial Efficiency

Oncology-Focused Webinars